Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold
- Shares drop 19 percent after-hours, partner Vertex also down
- ‘The FDA is going to be cautious,’ Baird analyst says
This article is for subscribers only.
Crispr Therapeutics AG plunged after the gene-editing company said a planned trial of its treatment to help people with sickle-cell disease was being put on hold by U.S. regulators.
Crispr is developing the therapy with Vertex Pharmaceuticals Inc., and the trial had yet to begin. The companies said in a statement Wednesday that the Food and Drug Administration placed a halt on the experiment until the agency could get more information from the companies.